Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial - Herbst, R S; Baas, P; Dong-Wan, K (Lancet, 2015)
et al.